Adventris is a biotechnology company that creates cancer immunotherapies by engineering high‑affinity, tumor‑specific antibodies, immune checkpoint modulators, and adoptive cell therapies. Its platform integrates protein engineering, biomarker discovery, and GMP‑compliant manufacturing to develop candidates for partnership with pharma and biotech firms, aiming to deliver durable anti‑tumor treatments.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer patients often face limited treatment options due to tumor resistance to conventional therapies and the inability of the immune system to recognize and eliminate malignant cells.
Solution
Adventris develops biotechnology solutions that harness and enhance the body’s immune response to target and destroy cancer cells. By engineering novel biologics and cellular platforms, the company aims to create therapies that can overcome tumor immune evasion and provide durable anti‑tumor activity. Their approach integrates advanced protein engineering, immune checkpoint modulation, and adoptive cell technologies to generate candidates suitable for clinical development. Adventris collaborates with pharmaceutical partners to advance these candidates through preclinical validation and regulatory pathways, ultimately delivering new immunotherapy options for oncology patients.
Target Audience
Primary customers include pharmaceutical and biotech companies seeking immunotherapy partners, as well as oncology research institutions developing next‑generation cancer treatments.
Features
- Proprietary protein engineering platform for high‑affinity, tumor‑specific antibodies
- Engineered immune checkpoint modulators designed to activate T‑cell responses within the tumor microenvironment
- Adoptive cell therapy pipelines utilizing genetically modified T‑cells and NK cells
- Integrated biomarker discovery workflow to identify predictive patient populations
- Scalable manufacturing processes compliant with GMP standards for biologics and cell products